Plain-English translation of NCT04195633 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Sickle cell disease research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new approach to stem cell transplantation for people with blood cancers and lymphomas. The study uses a chemotherapy drug called as part of the preparation before receiving donor stem cells, along with radiation and other standard medications. Researchers want to see if this new combination is safe and effective, and whether a lower dose of the medication works as well as a higher dose.
Stem cell transplants can cure some blood cancers, but the traditional preparation chemotherapy is very harsh on the body. This trial exists to find out whether this newer medication can work just as well while potentially causing less harm to healthy tissues.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive strong chemotherapy and radiation over about one week to prepare your body for the transplant, then receive donor stem cells on day zero. You will stay in the hospital for several weeks while your new immune system develops. After discharge, you will take several medications by mouth or IV to prevent rejection and manage side effects, with gradual tapering over months. You'll have frequent blood tests, scans, and bone marrow biopsies during the first year, with follow-up visits at 28 days, 56 days, 84 days, one year, and two years after transplant.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States